[Imatinib]

Gan To Kagaku Ryoho. 2003 Aug;30(8):1191-6.
[Article in Japanese]

Abstract

Imatinib mesylate is an inhibitor of Bcr/Abl tyrosine kinase, which essentially participates the pathogenesis of chronic myelogenous leukemia (CML). Imatinib is highly effective in the treatment of CML. Because imatinib also inhibits c-kit and platelet-derived growth-factor (PDGF) receptor, it may be efficacious against some tumors which possess c-kit or PDGF receptors.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Piperazines / pharmacology
  • Piperazines / therapeutic use*
  • Proto-Oncogene Proteins c-kit / drug effects*
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*
  • Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Proto-Oncogene Proteins c-kit
  • Receptors, Platelet-Derived Growth Factor